TMS denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies TMS as Not FDA-Approved — and How to Appeal

A "not FDA-approved" denial for transcranial magnetic stimulation (TMS) most commonly arises in one of two situations: (1) the specific TMS device or protocol being used has not received FDA 510(k) clearance or De Novo authorization for your particular diagnosis, or (2) Aetna's records or reviewer applied the wrong FDA-approval standard to a device that is, in fact, FDA-cleared. It is important to note that TMS devices have FDA clearance for specific indications — clearance for one diagnosis does not automatically extend to all uses. If your treatment falls within an FDA-cleared indication, the denial may simply reflect a documentation or reviewer error that is readily corrected on appeal.

## Why This Denial Is Appealable

If TMS is FDA-cleared for your specific diagnosis and the cleared protocol matches what your provider is recommending, the factual basis for the denial is incorrect and the appeal is straightforward: present the FDA clearance record and the prescription details showing they align. If your use is genuinely off-label (outside the cleared indication), the appeal shifts to demonstrating that the off-label use is supported by the applicable specialty guidelines and the published medical literature — off-label use of FDA-cleared devices is common clinical practice and insurers are not automatically permitted to deny coverage solely on that basis.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. Request the specific clinical rationale and the name of any policy the reviewer applied.
• External review (ACA §2719 / ERISA §503): After internal denial, request independent external review within approximately four months. External reviewers assess whether the FDA-approval basis for denial is clinically and factually sound — they frequently disagree with insurer determinations on FDA-status grounds.
• Expedited review: Available if delay would seriously harm your health.

## Documentation to Gather

1. FDA clearance documentation: Download the FDA 510(k) clearance summary or De Novo authorization for your specific TMS device and indication from fda.gov. This is the single most important document for this denial type. 2. Device and protocol details: The exact device model and treatment protocol your provider has prescribed — confirm it matches the cleared indication. 3. Prescriber letter: A letter from your treating clinician confirming that the prescribed device and protocol are FDA-cleared for your diagnosis, or — if off-label — explaining the clinical basis and referencing the applicable guideline organization. 4. Diagnosis records: Current clinical records confirming your diagnosis, severity, and treatment history. 5. Prior-treatment failure documentation: Dates and outcomes for prior treatments, showing TMS is being considered after appropriate prior steps.

## Criteria-Mapping Structure

Obtain Aetna's Clinical Policy Bulletin for TMS from Aetna.com. Identify each criterion involving FDA status and map it directly to: (1) the FDA clearance document, (2) your prescriber's device/protocol specification, and (3) your diagnosis confirmation. Present these as a numbered exhibit list. If the FDA clearance covers your use, state that clearly in the appeal cover letter's first paragraph — reviewers should be able to identify the dispositive fact immediately.